Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
1127studies shown
Showing 1,026-1,050 of 1,127
RecruitingNCT06947941

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

This study exists to explore whether this type of care could improve care and understanding. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Australia, Canada, Japan, United Kingdom, United States
Sponsor
Bristol-Myers Squibb
Condition
Schizophrenia
TerminatedNCT05211947

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand what a medication treatment could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 51 Years
Countries
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Romania, Serbia, Slovakia, South Korea, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
CompletedNCT04860830

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

This study exists to learn from real-world information that can show how questionnaires and follow-up reports fits into care. Researchers are trying to understand whether questionnaires and follow-up reports can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
Argentina, Austria, Belgium, Brazil, Bulgaria, China, Czech Republic, Denmark, Finland, Germany, Lithuania, Mexico, Portugal, Serbia, South Korea, Taiwan, United Kingdom, United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
CompletedNCT06315283

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

This study exists to see whether the medication TV-44749 can play a useful role in care. Researchers are trying to understand how people respond to the medication TV-44749 in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
Croatia, Spain, United Kingdom, United States
Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Condition
Schizophrenia
CompletedNCT05480046

Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse

This study exists to understand whether the medication Risperidone is both safe enough and useful enough to take further. Researchers are trying to understand whether the medication Risperidone can better prevent setbacks and support longer-term stability.

SchizophreniaOtherOver 18 Years
Countries
Germany, Italy, Portugal, Spain, United Kingdom
Sponsor
Rovi Pharmaceuticals Laboratories
Condition
Schizophrenia
CompletedNCT03677635

The Relationship Between Autobiographical Memory and Motivation

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United Kingdom
Sponsor
King's College London
Condition
Schizophrenia
TerminatedNCT03230097

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

This study exists to learn from real-world information that can show how questionnaires and follow-up reports fits into care. Researchers are trying to understand what questionnaires and follow-up reports could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 16 Years to 30 Years
Countries
Canada, China, United Kingdom, United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
CompletedNCT00460512

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia

This study exists to understand whether the medication Flexibly is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to the medication Flexibly in practice and what may need to be adjusted.

SchizophreniaOtherOver 18 Years
Countries
Belgium, Bulgaria, Croatia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Latvia, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Serbia, Spain, Sweden, Switzerland, Turkey, United Kingdom
Sponsor
Janssen-Cilag International NV
Condition
Schizophrenia
CompletedNCT02713282

A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

This study exists to explore whether the medication Transition could improve care and understanding. Researchers are trying to understand whether the medication Transition can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
Croatia, Denmark, France, Germany, Greece, Israel, Malaysia, Netherlands, Russian Federation, Saudi Arabia, South Korea, Spain, Taiwan, Turkey, United Kingdom
Sponsor
Janssen-Cilag Ltd.
Condition
Schizophrenia
CompletedNCT03809325

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

This study exists to explore whether questionnaires and follow-up reports could improve care and understanding. Researchers are trying to understand what questionnaires and follow-up reports could change in day-to-day care and decision-making.

SchizophreniaOtherOver 18 Years
Countries
Belgium, France, Germany, Hungary, Italy, Spain, United Kingdom
Sponsor
Janssen-Cilag International NV
Condition
Schizophrenia
RecruitingNCT06224530

Investigating the Effect of a Single-dose of Levetiracetam on Brain Function, Chemistry and Cognitive Performance in Psychosis Risk

This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
United Kingdom
Sponsor
King's College London
Condition
Schizophrenia
CompletedNCT04038957

A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 45 Years
Countries
United Kingdom
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
RecruitingNCT05127278

E-Detection Tool for Emerging Mental Disorders

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 12 Years to 35 Years
Countries
United Kingdom
Sponsor
King's College London
Condition
Schizophrenia
RecruitingNCT06703827

Effects of Online Metacognitive Training Group on Distressing Beliefs

This study exists to see whether cognitive behavioural therapy, a structured talking treatment, can play a useful role in care. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United Kingdom
Sponsor
City, University of London
Condition
Schizophrenia
CompletedNCT05670197

Service User and Staff Views on Digital Remote Monitoring for Psychosis

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can better prevent setbacks and support longer-term stability.

SchizophreniaOtherOver 16 Years
Countries
United Kingdom
Sponsor
Manchester Academic Health Science Centre
Condition
Schizophrenia
CompletedNCT01972711

Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics

This study exists to explore whether blood tests and biological markers could improve care and understanding. Researchers are trying to understand what blood tests and biological markers can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 45 Years
Countries
United Kingdom
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT03093064

Inflammatory Response In Schizophrenia

This study exists to learn from real-world information that can show how brain scans or other body measurements fits into care. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
United Kingdom
Sponsor
King's College London
Condition
Schizophrenia
CompletedNCT06190483

Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk

This study exists to compare options and see whether blood tests and biological markers offers something meaningfully different. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
United Kingdom
Sponsor
King's College London
Condition
Schizophrenia
CompletedNCT03859973

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand what a medication treatment can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
Australia, Canada, France, New Zealand, United Kingdom, United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
CompletedNCT05633108

A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders

This study exists to compare options and see whether a therapy or guided support program offers something meaningfully different. Researchers are trying to understand whether a therapy or guided support program can better prevent setbacks and support longer-term stability.

SchizophreniaOtherOver 18 Years
Countries
United Kingdom
Sponsor
Eisai Co., Ltd.
Condition
Schizophrenia
CompletedNCT04605393

Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United Kingdom
Sponsor
King's College London
Condition
Schizophrenia
CompletedNCT04180709

CBT to Reduce Insomnia and Improve Social Recovery in Early Psychosis

This study exists to understand how cognitive behavioural therapy, a structured talking treatment, holds up over time after the earliest research stage. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherOver 18 Years
Countries
United Kingdom
Sponsor
University of Cambridge
Condition
Schizophrenia
CompletedNCT05377294

Acceptability and Feasibility of MOL in Acute Inpatient Units

This study exists to see whether a therapy or guided support program is workable and worth testing more broadly. Researchers are trying to understand how people respond to a therapy or guided support program in practice and what may need to be adjusted.

SchizophreniaOtherOver 18 Years
Countries
United Kingdom
Sponsor
University of Manchester
Condition
Schizophrenia
CompletedNCT03114917

Cognitive AppRoaches to coMbatting Suicidality

This study exists to see whether a therapy or guided support program can play a useful role in care. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherOver 18 Years
Countries
United Kingdom
Sponsor
University of Manchester
Condition
Schizophrenia
United Kingdom | Clinical Trials | HopeStage Research